Zydus Lifesciences has received USFDA approval for its generic Eltrombopag tablets, strengthening its U.S. generics portfolio and opening access to a blood disorder drug with strong commercial potential.
As health-tech startups and pharmaceutical innovators drive rapid adoption of injectable weight-loss drugs, new UK research has raised questions about their durability as long-term obesity solutions. While medications such as semaglutide (Wegovy...
Venus Remedies has received regulatory approval in Indonesia for ceftazidime+avibactam, enabling the country’s first generic launch and marking the company’s entry into the anti-infective segment in the key ASEAN market.
Bionpharma has received US FDA approval for its generic Etravirine tablets, developed using STEERLife’s FragMelt platform. This milestone marks a breakthrough in pharmaceutical manufacturing, offering a cost-effective HIV treatment option.
Dr. Reddy's Laboratories has introduced the OTC Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. market, offering relief from itchy eyes due to common allergens. This first-to-market launch reinforces the company's growing presence
Biocon Pharma, a subsidiary of Biocon Ltd, has received approval from the United States Food and Drug Administration (US FDA) for its generic everolimus tablets for oral suspension. The approval was granted under an Abbreviated New Drug Applicatio...
Boston Scientific Corporation has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical device company focused on therapies for bladder dysfunction. The acquisition strengthens Boston Scientifi..
Alembic Pharmaceuticals has clinched tentative approval from the US Food & Drug Administration (USFDA) for its Bosutinib Tablets, 400?mg — a major generic cancer drug move that expands its foothold in the lucrative US oncology market...
Bristol Myers Squibb today reported positive Phase 3 results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data come from the Phase 3 SCOUT-HCM trial, the first study of a cardiac myosin inhibitor...
Eli Lilly and Company announced today a major partnership with NVIDIA to launch a first-of-its-kind AI co-innovation lab designed to take on some of the pharmaceutical industry’s hardest problems. The collaboration will see the two companies...
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")